Suppr超能文献

FTY720与肺肿瘤发展

FTY720 and lung tumor development.

作者信息

Salinas Natália Regina Antunes, Oshima Celina Tizuko Fujiyama, Cury Patrícia Maluf, Cordeiro José Antonio, Bueno Valquiria

机构信息

Division of Immunology, UNIFESP-Federal University of São Paulo, R. Botucatu 862, São Paulo, Brazil.

出版信息

Int Immunopharmacol. 2009 Jun;9(6):689-93. doi: 10.1016/j.intimp.2008.12.007. Epub 2009 Jan 13.

Abstract

FTY720 has been shown to prevent cancer development in experimental models but there is no report whether this beneficial effect is associated with the time point of the drug administration. Lung adenoma was induced in mice by urethane injection followed by different periods of FTY720 administration in order to evaluate lung tumor development. BALB/c mice received urethane intraperitoneally in two doses of 1.5 g/kg and were submitted to five daily doses of FTY720 (1 mg/kg/day) starting just after urethane injection (G2 n=5), 4 weeks after urethane injection (G3 n=10), 8 weeks after urethane injection (G4 n=10) and no FTY720 administration (G1 n=5). Twenty-four weeks after urethane administration mice were evaluated for the number of leukocyte in blood, lymphocytes in spleen, and lungs were evaluated for changes in histology, PCNA and VEGF expression. Lung nodules were present in higher numbers both in non treated (G1; 0.0-7.0) and FTY720 treated 8 weeks after urethane injection (G4; 0.0-6.0). G4 Group also presented the highest number of papillary nodules. G1 and G4 groups presented the lower number of splenocytes and neutrophils. In early time FTY720 treated mice (G2) we observed a slight decrease in PCNA staining and also the lower percentage of VEGF intense staining. Therefore, our data suggest that the benefits of FTY720 treatment are time-dependent and when administered in early periods after lung tumor induction this drug could impair cancer development.

摘要

FTY720已被证明在实验模型中可预防癌症发展,但尚无关于这种有益效果是否与药物给药时间点相关的报道。通过氨基甲酸乙酯注射诱导小鼠肺腺瘤,随后给予不同时间段的FTY720,以评估肺肿瘤的发展。BALB/c小鼠腹腔注射两剂1.5 g/kg的氨基甲酸乙酯,并在氨基甲酸乙酯注射后立即开始接受五剂每日剂量的FTY720(1 mg/kg/天)(G2,n = 5),氨基甲酸乙酯注射后4周(G3,n = 10),氨基甲酸乙酯注射后8周(G4,n = 10),且不给予FTY720(G1,n = 5)。氨基甲酸乙酯给药24周后,评估小鼠血液中的白细胞数量、脾脏中的淋巴细胞数量,并评估肺组织学、PCNA和VEGF表达的变化。未治疗组(G1;0.0 - 7.0)和氨基甲酸乙酯注射8周后接受FTY720治疗组(G4;0.0 - 6.0)的肺结节数量均较多。G4组还呈现出最高数量的乳头状结节。G1组和G4组的脾细胞和中性粒细胞数量较少。在早期接受FTY720治疗的小鼠(G2)中,我们观察到PCNA染色略有下降,VEGF强染色的百分比也较低。因此,我们的数据表明,FTY720治疗的益处具有时间依赖性,并且在肺肿瘤诱导后的早期给药时,这种药物可能会损害癌症发展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验